Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

26.81 +1.14 (+4.42%)
Streaming Delayed Price Updated: 3:21 PM EDT, Jun 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
Via ACCESSWIRE
Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)
Via ACCESSWIRE
Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate
Via ACCESSWIRE
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
From Personalis, Inc.
Via Business Wire
Moderna Announces Advances Across mRNA Pipeline and Provides Business Update
Via ACCESSWIRE
Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
Via ACCESSWIRE
Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
Via ACCESSWIRE
Novavax Shares Jumped in January While Others Slipped
Updated FDA Covid vaccine policy could've boosted NVAX shares at the end of January, when other pharma stocks slipped, but it may not affect the bottom line. 
Via MarketBeat
Exposures COVID-19 Product Safety
Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
Via ACCESSWIRE
Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road. 
Via MarketBeat
Exposures Product Safety
Moderna to Acquire OriCiro Genomics
Via ACCESSWIRE
Moderna Finalizes Strategic Partnership with UK Government
Via ACCESSWIRE
Chantal Friebertshäuser Joins Moderna as Senior Vice President, Commercial
Via ACCESSWIRE
How Could GSK's RSV Vaccine Change its Valuation?
GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future. 
Via MarketBeat
Exposures Product Safety
Moderna and Pfizer Race to Release RSV Vaccines
Two of the largest vaccine producers have engaged in the rapid development of RSV vaccines, here's how the companies are tracking so far. 
Via MarketBeat
Exposures Product Safety
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults
Via ACCESSWIRE
Moderna to Provide Business and Pipeline Updates at the 2023 J.P. Morgan Healthcare Conference
Via ACCESSWIRE
Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age
Via ACCESSWIRE
Brad Miller Joins Moderna as Chief Information Officer
Via ACCESSWIRE
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna’s BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union
Via ACCESSWIRE
Harpoon Therapeutics Remains Volatile After Promising News
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%. 
Via MarketBeat
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Via ACCESSWIRE
Moderna to Present at the Piper Sandler 34th Annual Healthcare Conference
Via ACCESSWIRE
David Jiménez Joins Moderna As U.S. General Manager
Via ACCESSWIRE
Moderna Tops BioSpace's Best Places to Work Ranking for Second Consecutive Year
Via ACCESSWIRE
While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants
EQNX::TICKER_START (OTCQB:BIXT),(NASDAQ:NVAX),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:INO),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial
Via ACCESSWIRE
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
Learn more about Organicell Regenerative Medicine, Inc.from this latest report. 
Via TheNewswire.com
Exposures COVID-19 Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.